{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:58:35Z","timestamp":1755799115584,"version":"3.44.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ahjo.2025.100587","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T23:38:24Z","timestamp":1754350704000},"page":"100587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Serum uric acid, renal status, cardiovascular-kidney-metabolic syndrome and drug therapy, a wide-angled Mendelian randomization analysis"],"prefix":"10.1016","volume":"57","author":[{"given":"Lingyun","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuelian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.ahjo.2025.100587_bb0005","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical Management of Cardiovascular-Kidney-Metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.ahjo.2025.100587_bb0010","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.ahjo.2025.100587_bb0015","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of Total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.ahjo.2025.100587_bb0020","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2174\/092986707781058797","article-title":"Uric acid reduction: a new paradigm in the management of cardiovascular risk?","volume":"14","author":"Dawson","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ahjo.2025.100587_bb0025","first-page":"103","article-title":"Uric acid in metabolic syndrome: does uric acid have a definitive role?","author":"Copur","year":"2022","journal-title":"Eur. J. Intern. Med."},{"issue":"1","key":"10.1016\/j.ahjo.2025.100587_bb0030","doi-asserted-by":"crossref","DOI":"10.1177\/00033197211012546","article-title":"The role of uric acid in the acute myocardial infarction: a narrative review","volume":"73","author":"Demiray","year":"2022","journal-title":"Angiology"},{"issue":"19","key":"10.1016\/j.ahjo.2025.100587_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/nu14194095","article-title":"The prevalence of hyperuricemia and its correlates among adults in China: results from CNHS 2015-2017","volume":"14","author":"Piao","year":"2022","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.ahjo.2025.100587_bb0040","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1053\/j.ajkd.2010.06.004","article-title":"Uric acid, CKD, and cardiovascular disease: confounders, culprits, and circles","volume":"56","author":"Tangri","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ahjo.2025.100587_bb0045","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1146\/annurev.me.39.020188.002341","article-title":"Serum creatinine and renal function","volume":"39","author":"Levey","year":"1988","journal-title":"Annu. Rev. Med."},{"issue":"5","key":"10.1016\/j.ahjo.2025.100587_bb0050","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1046\/j.1523-1755.2003.00924.x","article-title":"Review on uremic toxins: classification, concentration, and interindividual variability","volume":"63","author":"Vanholder","year":"2003","journal-title":"Kidney Int."},{"issue":"19","key":"10.1016\/j.ahjo.2025.100587_bb0055","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1001\/jama.2017.17219","article-title":"Mendelian randomization","volume":"318","author":"Emdin","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ahjo.2025.100587_bb0060","article-title":"Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians","volume":"362","author":"Davies","year":"2018","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ahjo.2025.100587_bb0065","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038984","article-title":"Multivariable mendelian randomization and mediation","volume":"11","author":"Sanderson","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"3","key":"10.1016\/j.ahjo.2025.100587_bb0070","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/ije\/dyq151","article-title":"Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants","volume":"40","author":"Pierce","year":"2011","journal-title":"Int. J. Epidemiol."},{"issue":"12","key":"10.1016\/j.ahjo.2025.100587_bb0075","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1093\/aje\/kwr026","article-title":"Instrumental variable estimation of causal risk ratios and causal odds ratios in Mendelian randomization analyses","volume":"173","author":"Palmer","year":"2011","journal-title":"Am. J. Epidemiol."},{"issue":"5","key":"10.1016\/j.ahjo.2025.100587_bb0080","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","article-title":"Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases","volume":"50","author":"Verbanck","year":"2018","journal-title":"Nat. Genet."},{"issue":"17","key":"10.1016\/j.ahjo.2025.100587_bb0085","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ahjo.2025.100587_bb0090","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10654-021-00757-1","article-title":"Mendelian randomisation for mediation analysis: current methods and challenges for implementation","volume":"36","author":"Carter","year":"2021","journal-title":"Eur. J. Epidemiol."},{"issue":"D1","key":"10.1016\/j.ahjo.2025.100587_bb0095","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.ahjo.2025.100587_bb0100","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0149-2918(04)90078-1","article-title":"Simple solution to a common statistical problem: interpreting multiple tests","volume":"26","author":"Gordi","year":"2004","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ahjo.2025.100587_bb0105","article-title":"Modifiable pathways in Alzheimer\u2019s disease: Mendelian randomisation analysis","volume":"359","author":"Larsson","year":"2017","journal-title":"BMJ (Clin. Res. Ed)."},{"issue":"2","key":"10.1016\/j.ahjo.2025.100587_bb0110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1053\/j.ajkd.2010.06.004","article-title":"Uric acid, CKD, and cardiovascular disease: confounders, culprits, and circles","volume":"56","author":"Tangri","year":"2010","journal-title":"Am. J. Kidney Dis."},{"issue":"4","key":"10.1016\/j.ahjo.2025.100587_bb0115","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40265-016-0550-y","article-title":"Lesinurad: first global approval","volume":"76","author":"Hoy","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ahjo.2025.100587_bb0120","doi-asserted-by":"crossref","DOI":"10.1177\/11795468241239542","article-title":"Impact of hyperuricemia and urate-lowering agents on cardiovascular diseases","volume":"18","author":"Sosa","year":"2024","journal-title":"Clin. Med. Insights Cardiol."},{"issue":"10","key":"10.1016\/j.ahjo.2025.100587_bb0125","first-page":"1581","article-title":"Serum uric acid levels and the risk of obesity: a longitudinal population-based epidemiological study","volume":"63","author":"Zheng","year":"2017","journal-title":"Clin. Lab."},{"key":"10.1016\/j.ahjo.2025.100587_bb0130","doi-asserted-by":"crossref","first-page":"9691345","DOI":"10.1155\/2019\/9691345","article-title":"Effects of uric acid on diabetes mellitus and its chronic complications","volume":"2019","author":"Xiong","year":"2019","journal-title":"Int. J. Endocrinol."},{"issue":"7","key":"10.1016\/j.ahjo.2025.100587_bb0135","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/ajh\/hpaa044","article-title":"Uric acid and hypertension: an update with recommendations","volume":"33","author":"Sanchez-Lozada","year":"2020","journal-title":"Am. J. Hypertens."},{"issue":"9","key":"10.1016\/j.ahjo.2025.100587_bb0140","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/HYPERTENSIONAHA.122.17956","article-title":"Uric acid and hypertension: a review of evidence and future perspectives for the Management of Cardiovascular Risk","volume":"79","author":"Borghi","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.ahjo.2025.100587_bb0145","doi-asserted-by":"crossref","first-page":"1215521","DOI":"10.3389\/fendo.2023.1215521","article-title":"The association between serum uric acid and hypertriglyceridemia: evidence from the national health and nutrition examination survey (2007-2018)","volume":"14","author":"Tan","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"5","key":"10.1016\/j.ahjo.2025.100587_bb0150","first-page":"586","article-title":"Serum uric acid levels and risk of incident hypertriglyceridemia: a longitudinal population-based epidemiological study","volume":"47","author":"Zheng","year":"2017","journal-title":"Ann. Clin. Lab. Sci."},{"issue":"1","key":"10.1016\/j.ahjo.2025.100587_bb0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","article-title":"Uric acid and risk of heart failure: a systematic review and meta-analysis","volume":"16","author":"Huang","year":"2014","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.ahjo.2025.100587_bb0160","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ehf2.14535","article-title":"Uric acid is a biomarker for heart failure, but not therapeutic target: result from a comprehensive meta-analysis","volume":"11","author":"Qin","year":"2024","journal-title":"ESC Heart Fail."},{"issue":"3","key":"10.1016\/j.ahjo.2025.100587_bb0165","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027089","article-title":"Elevated uric acid is associated with new-onset atrial fibrillation: results from the Swedish AMORIS Cohort","volume":"12","author":"Ding","year":"2023","journal-title":"J. Am. Heart Assoc."},{"issue":"8","key":"10.1016\/j.ahjo.2025.100587_bb0170","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1093\/ndt\/gfq740","article-title":"Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem lipid research clinic cohort study","volume":"26","author":"Ben-Dov","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"issue":"19","key":"10.1016\/j.ahjo.2025.100587_bb0175","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1001\/jama.2019.4329","article-title":"Association of household income with life expectancy and cause-specific mortality in Norway, 2005-2015","volume":"321","author":"Kinge","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ahjo.2025.100587_bb0180","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1016\/j.cell.2021.04.010","article-title":"Interdisciplinary approaches are fundamental to decode the biology of adversity","volume":"184","author":"Baumer","year":"2021","journal-title":"Cell"},{"issue":"25","key":"10.1016\/j.ahjo.2025.100587_bb0185","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.jacc.2019.04.043","article-title":"Mechanistic understanding of socioeconomic disparities in cardiovascular disease","volume":"73","author":"Miller","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.ahjo.2025.100587_bb0190","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCRESAHA.121.319811","article-title":"Social determinants of cardiovascular disease","volume":"130","author":"Powell-Wiley","year":"2022","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.ahjo.2025.100587_bb0195","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: mechanisms and advances in therapy","volume":"9","author":"Du","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.ahjo.2025.100587_bb0200","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/HJH.0000000000002600","article-title":"Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid right for heArt health study","volume":"39","author":"Maloberti","year":"2021","journal-title":"J. Hypertens."},{"issue":"1","key":"10.1016\/j.ahjo.2025.100587_bb0205","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12933-025-02707-7","article-title":"Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF","volume":"24","author":"Luo","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ahjo.2025.100587_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112204","article-title":"Metabolic crosstalk and therapeutic interplay between diabetes and hyperuricemia","volume":"224","author":"Yang","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ahjo.2025.100587_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132527","article-title":"Uric acid and metabolic syndrome: importance of hyperuricemia cut-off","volume":"417","author":"Maloberti","year":"2024","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"10.1016\/j.ahjo.2025.100587_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2024.103792","article-title":"Two still unanswered questions about uric acid and cardiovascular prevention: is a specific uric acid cut-off needed? Is hypouricemic treatment able to reduce cardiovascular risk?","volume":"35","author":"Maloberti","year":"2025","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"19","key":"10.1016\/j.ahjo.2025.100587_bb0225","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026301","article-title":"Lowering uric acid may improve prognosis in patients with hyperuricemia and heart failure with preserved ejection fraction","volume":"11","author":"Nishino","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"8","key":"10.1016\/j.ahjo.2025.100587_bb0230","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10654-024-01138-0","article-title":"A phenome-wide association and factorial Mendelian randomization study on the repurposing of uric acid-lowering drugs for cardiovascular outcomes","volume":"39","author":"Wang","year":"2024","journal-title":"Eur. J. Epidemiol."},{"issue":"10","key":"10.1016\/j.ahjo.2025.100587_bb0235","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1001\/jamacardio.2024.2435","article-title":"Verinurad plus allopurinol for heart failure with preserved ejection fraction: the AMETHYST randomized clinical trial","volume":"9","author":"Kitzman","year":"2024","journal-title":"JAMA Cardiol."}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602225000904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602225000904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T16:12:30Z","timestamp":1755619950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602225000904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":47,"alternative-id":["S2666602225000904"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2025.100587","relation":{},"ISSN":["2666-6022"],"issn-type":[{"type":"print","value":"2666-6022"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum uric acid, renal status, cardiovascular-kidney-metabolic syndrome and drug therapy, a wide-angled Mendelian randomization analysis","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2025.100587","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100587"}}